Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer
Vanita Noronha*, Kumar Prabhash*, Amit Joshi*, Vijay Maruti Patil*, Sanjay Talole†, Dipti Nakti*, Arvind Sahu*, Srushti Shah‡, Sarbani Ghosh-Laskar§, Prachi S. Patil¶, Shaesta A. Mehta¶, Nirmala Jambhekar#, Abhishek Mahajan**, Nilendu Purandare††
Oncology Research, Vol.23, No.4, pp. 183-195, 2015, DOI:10.3727/096504016X14537290676865
Abstract There are little data on the efficacy and safety of taxane/platinum with definitive radiotherapy (RT) for esophageal/GEJ cancer. This article is a retrospective analysis of patients who received weekly paclitaxel 50 mg/
m2
and carboplatin AUC 2 with radical definitive RT for locally advanced esophageal/GEJ cancer. Between
February 2011 and July 2014, 179 patients were included. The median age was 54 years. Ninety-two percent
of patients had squamous histology. Mean RT dose was 58.7 Gy in 32 fractions over 53 days, with mean of
six chemotherapy cycles. Fifty-six percent of patients developed ³grade 3 acute… More >